Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-12-07
2009-06-02
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S169000, C546S153000
Reexamination Certificate
active
07541466
ABSTRACT:
Tetrahydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.
REFERENCES:
patent: 5776677 (1998-07-01), Tsui et al.
patent: 6100238 (2000-08-01), Gyorkos et al.
patent: 6180619 (2001-01-01), Kim
patent: 6720330 (2004-04-01), Hay et al.
patent: 6730777 (2004-05-01), Tsui et al.
patent: 6902907 (2005-06-01), Tsui et al.
patent: 6984487 (2006-01-01), Tsui et al.
patent: WO 94/04671 (1994-03-01), None
patent: 03006014 (2003-01-01), None
Su, Bioorganic & Med Chem Lett, vol. 11(22), pp. 2974-2950, 2001.
Vendeville, Bioorg & Med Chem, vol. 10(6), pp. 1719-1729, 2002.
Gibson, Eu J of Med Chem, vol. 37(5), pp. 379-389, 2002.
Hyde, Biochemistry, VOI 42(21), pp. 6475-6483, 2003.
Pedemonte, J Clin inventigation, vol. 115(9), pp. 2564-2571, 2005.
VanGoor, Am J pyysiol Lung Cell Mol Physiol, vol. 290, pp. L1117-L1130, 2006.
Lobell J of Biomol Screening, VOI 8(4), pp. 430-438, 2003.
Van Goor, F., et al., “Rescue of ΔF508 CFTR Trafficking and Gating in Human Cystic Fibrosis Airway Primary Cultures by Small Molecules,”Am. J. Physiol. Lung Cell Mol. Physiol., doi: 10.1152/ajplung.00169.2005, pp. 1-57 (2006).
Hirth, B. H., et al., “Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport,”Bioorg. Med. Chem. Lett., 15: 2087-2091(2005). Available online at www.sciencedirect.com.
Aridor, M. , et al., “Traffic Jam: A Compendium of Human Diseases that Affect Intracellular Transport Processes,”Traffic, 1: 836-851 (2000).
Arispe, N., et al. “Direct Activation of Cystic Fibrosis Transmembrane Conductance Regulator Channels by 8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-Diallyl-8-cyclohexylxanthine (DAX),”J. Biol. Chem., 273(10): 5727-5734 (1998).
Brown, C.R., et al., “Chemical Chaperones Correct the Mutant Phenotype of the ▴F508 Cystic Fibrosis Transmembrane Conductance Regulator Protein,”Cell Stress and Chaperones, 1(2): 117-125 (1996).
Cheng, S.H., et al., “Functional Activation of the Cystic Fibrosis Trafficking Mutant ▴F508-CFTR by Overexpression,”Am. J. Physiol., 268: L615-L624 (1995).
Denning, et al., “Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator is Temperature-Sensitive,”Nature, 358: 761-764 (1992).
Dormer, R.L., et al., “Correction of delF508-CFTR Activity with Benzo(c)quinolizinium Compounds Through Facilitation of its Processing in Cystic Fibrosis Airway Cells,”J. Cell Science, 114: 4073-4081 (2001).
Egan, M.E., et al., “Calcium-Pump Inhibitors Induce Functional Surface Expression of ▴F508-CFTR Protein in Cystic Fibrosis Epithelial Cells,”Nature Medicine, 8(5): 485-492 (2002).
Fischer, H., et al., “Partial Restoration of Defective Chloride Conductance in ▴F508 CF Mice by Trimethylamine Oxide,”Am. J. Physiol. Lung Cell. Mol. Physiol., 281: L52-L57 (2001).
Hwang, T.C., et al., “Genistein Potentiates Wild-Type and ▴F508-CFTR Channel Activity,”Am. J. Physiol., 273: C988-C998 (1997).
Jiang, C., et al., “Partial Restoration of cAMP-Stimulated CFTR Chloride Channel Activity in ▴F508 Cells by Deoxyspergualin,”Am. J. Physiol., 275: C171-C178 (1998).
Moyer, B.D., et al., “A New Frontier in Pharmacology: The Endoplasmic Reticulum as a Regulated Export Pathway in Health and Disease,”Emerging Therapeutic Targets, 5: 165-176 (2001).
Riordan, J.R., “The Cystic Fibrosis Transmembrane Conductance Regulator,”Ann. Rev. Physiol., 55: 609-630 (1993).
Rosenstein, B.R., et al., “Cystic Fibrosis,”Lancet, 351: 277-282 (1998).
Rubinstein, et al., “In Vitro Pharmacologic Restoration of CFTR-Mediated Chloride Transport with Sodium-4-Phenylbutyrate in Cystic Firbrosis Epithelial Cells Containing ▴F508-CFTR,”J. Clin. Invest., 100: 2457-2465 (1997).
Verkman, A.S., “Development and Biological Applications of Chloride-Sensitive Fluoroscent Indicators,”Am. J. Physiol, 259: C375-C388 (1990).
Welsh, M.J., et al., “Molecular Mechanisms of CFTR Chloride Channel Dysfunction in Cystic Fibrosis,”Cell, 73: 1251-1254 (1993).
Yankaskas, et al., “Papilloma Virus Immortalized Tracheal Epithelial Cells Retain a Well-Differentiated Phenotype,”Am. J. Physiol., 264: C1219-C1230 (1993).
Zeitlin, P.L., et al., “Evidence of CFTR Function in Cystic Fibrosis After Systemic Administration of 4-Phenylbutyrate,”Molecular Therapy, 6: 119-126 (2002).
Welsh, M.J., et al., Ch. 201: “Cystic Fibrosis.” InThe Metabolic and Molecular Bases of Inherited Disease, 8thEdition, online, Ed by Scriver, C.L., et al., (McGraw Hill) (2001).
Cuff Lisa
Gregory Jill
Hirth Bradford H.
Kane, Jr. John L.
Pregel Marko J.
Blundell Isabelle A. S.
Genzyme Corporation
Seaman D. Margaret
LandOfFree
Tetrahydroisoquinoline derivatives for treating protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinoline derivatives for treating protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinoline derivatives for treating protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081237